NeuroDerm (NASDAQ:NDRM) +14.7% premarket after agreeing to be acquired by Japan's Mitsubishi Tanabe Pharma (OTCPK:MTZPY) for $39/share, a 17% premium over Friday's closing price and implying a ~$1.1B equity value.
The deal is the largest ever acquisition of an Israeli pharmaceuticals company.
The Japanese drugmaker says it will leverage NDRM's Parkinson's disease drug product that has begun clinical trials in the U.S. and Europe.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.